VRTX FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the pharmaceutical company will earn $15.55 per share for the year, down from their previous forecast of $15.60. Cantor Fitzgerald has a "Overweight" rating and a $535.00 price target on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

A number of other research firms also recently weighed in on VRTX. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Bank of America raised their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. The Goldman Sachs Group reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, HC Wainwright reiterated a "buy" rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Fourteen research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $511.62.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded up $0.57 during mid-day trading on Thursday, reaching $479.53. The stock had a trading volume of 932,539 shares, compared to its average volume of 1,424,288. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The firm has a market cap of $123.14 billion, a PE ratio of -122.33 and a beta of 0.41. The firm's 50 day simple moving average is $448.74 and its 200 day simple moving average is $459.47. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the previous year, the business posted $4.76 EPS. The firm's quarterly revenue was up 2.6% on a year-over-year basis.

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of VRTX. Quent Capital LLC boosted its position in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock valued at $249,000 after purchasing an additional 22 shares during the last quarter. Truvestments Capital LLC lifted its position in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Advisor OS LLC boosted its stake in Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock valued at $263,000 after purchasing an additional 23 shares during the period. Moors & Cabot Inc. increased its position in Vertex Pharmaceuticals by 0.7% during the fourth quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company's stock worth $1,451,000 after acquiring an additional 25 shares during the period. Finally, Sculati Wealth Management LLC grew its position in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock worth $1,029,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.